Press release 📈 Stocks 🌍 China

Laekna to Present Preclinical Data on Obesity Drug Candidate LAE124

Laekna will present preclinical data for its oral obesity drug candidate LAE124 at the 44th Annual Meeting of The Obesity Society in Washington, D.C., on November 15, 2026.

📅 November 12, 2026 🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: 2105.HK → 2/10 (70% confidence).

📊 Affected Assets (1)

2105.HK

Neutral 🤖 70%

⚡ Intraday 🌍 CN · Explicit

Laekna announces a poster presentation on LAE124, an oral small-molecule Amylin/Calcitonin receptor agonist still in IND-enabling studies, with only animal (DIO rat) data on food intake, weight reduction and PK profile. This is early-stage pipeline visibility without clinical or financial figures, so it is unlikely to materially move the share price over the coming days.

Catalysts

• Poster presentation on 15 November 2026 at Obesity Week 2026 in Washington, D.C.

Risk Factors

• LAE124 is only in IND-enabling studies with no human data yet
• Preclinical animal results may not translate to humans

🎯 Key Takeaways

Laekna will present poster number 465 on LAE124 at Obesity Week 2026 on November 15, 2026.
LAE124 is an oral small-molecule dual Amylin/Calcitonin receptor agonist currently in IND-enabling studies.
Animal studies showed LAE124 produced dose-dependent weight reduction and a favorable pharmacokinetic profile in DIO rats.
The drug is designed for once-daily oral dosing to improve patient adherence compared to existing injectable peptide therapies.

📝 Executive Summary

Laekna (2105.HK) announced that its oral small-molecule dual Amylin/Calcitonin receptor agonist, LAE124, will be featured in a poster presentation at Obesity Week 2026. Currently in IND-enabling studies, the candidate demonstrated dose-dependent weight reduction and a favorable pharmacokinetic profile in animal models.

❓ FAQ

Does this announcement contain any clinical or financial results for Laekna?

No. LAE124 is in IND-enabling studies and the data shown are from animal studies, including dose-dependent weight reduction in DIO rats and a favorable animal PK and safety profile. No revenue, profit or clinical trial figures are disclosed.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article